

**REMARKS**

Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a disk copy of the Substitute Sequence Listing. The disk copy of the Sequence Listing, file “2007-07-13 3493-0157PUS1.txt”, is identical to the paper copy, except that it lacks formatting. The paper and CRF copies of the Sequence Listing **do not add new matter** into the application.


The Sequence Listing is amended to more properly describe the Xaa residues representing multiple amino acids found in SEQ ID NOS: 1-4 and 8-11. No new matter is introduced by these amendments.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By

  
Andrew D. Meikle, #32,868

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

ADM/psq  
3493-0157PUS1

Attachments:      Disk Copy of Substitute Sequence Listing  
                            Paper Copy of Substitute Sequence Listing